23andMe Stock Jumps 8% on GLP-1 Genetic Predictor Study

(PALO ALTO, Calif.) — 23andMe Holding Co. (ME) announced on Wednesday its research institute has identified genetic predictors for both the effectiveness and side effects of GLP-1 weight loss drugs, a finding that could personalize prescriptions for the blockbuster medications.

"This study is a significant step toward a future of personalized medicine for weight management," said a lead researcher at the 23andMe Research Institute. "By understanding the genetic basis of how individuals respond to GLP-1s, we can help maximize efficacy and minimize adverse effects."

The research, published today, analyzed data from 23andMe customers who consented to participate. It found specific genetic variants associated with a higher likelihood of successful weight loss on GLP-1 medications, such as semaglutide and liraglutide. The study also identified genetic markers linked to a greater risk of side effects like nausea and vomiting.

The discovery creates a new, potentially lucrative application for 23andMe's vast repository of genetic data. The company's stock rose as much as 8% in pre-market trading following the announcement. The findings could pave the way for partnerships with pharmaceutical companies to develop companion diagnostic tests for the multi-billion dollar GLP-1 market.

This development suggests a new commercial path for 23andMe, leveraging its genetic database to create value in the rapidly growing obesity drug market. Investors will be watching for any announcements of formal partnerships with GLP-1 manufacturers, which could provide a significant new revenue stream.

This article is for informational purposes only and does not constitute investment advice.